Blog: JASPER THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) – Marketscreener.com

Item 7.01. Regulation FD Disclosure.

On January 13, 2023, Jasper Therapeutics, Inc. issued a press release announcing
that new positive data for briquilimab (formerly known as JSP191) will be
presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy
Meetings of ASTCT and CIBMTR taking place on February 15-19, 2023 in Orlando,
Florida. A copy of the press release is furnished herewith as Exhibit 99.1 to
this Current Report on Form 8-K.

The information in this Item 7.01, including the press release attached hereto
as Exhibit 99.1, is being furnished under Item 7.01 of Form 8-K and shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, and it shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.



Exhibit No.   Description
   99.1         Press Release, dated January 13, 2023.
    104       Cover Page Interactive Data File, formatted in Inline Extensible
              Business Reporting Language (iXBRL).




                                       1

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s